Jeffrey Harris, MD
Pulmonary Disease · Saint Louis, MONPI 1922070812
Payments from drug & device makers
Across 321 payments — averaging $3565.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Molecular Systems, Inc.$1.1M
- GSK$702
- Jazz Pharmaceuticals Inc.$608
- Harmony Biosciences LLC$577
- AstraZeneca$498
- Insmed, Inc.$314
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,34697%
- Education$1123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Molecular Systems, Inc. | 56 | $1,140,026 |
| GSK | 62 | $702 |
| Jazz Pharmaceuticals Inc. | 41 | $608 |
| Harmony Biosciences LLC | 17 | $577 |
| AstraZeneca | 30 | $498 |
| Insmed, Inc. | 14 | $314 |
| Regeneron Healthcare Solutions, Inc. | 9 | $231 |
| Sanofi | 9 | $198 |
| Axsome Therapeutics, Inc. | 11 | $185 |
| Teva Pharmaceuticals USA, Inc. | 13 | $146 |
| Philips North America LLC | 7 | $125 |
| Resmed Corp | 4 | $102 |
| Boehringer Ingelheim | 4 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Alcon | 3 | $69 |
| Electromed, Inc. | 6 | $60 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $45 |
| Verona Pharma, Inc. | 3 | $44 |
| Eisai Inc. | 3 | $42 |
| Pfizer | 3 | $40 |
| Grifols USA, LLC | 2 | $40 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Merck | 2 | $27 |
| Mylan Specialty L.p. | 2 | $27 |
| AbbVie | 2 | $24 |
| Amgen | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Baxter Healthcare | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Fisher & Paykel Healthcare Inc | 1 | $13 |
How this compares
$1,144,484 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 298 | $249,749 |
| XyremSodium Oxybate | 12 | $215,160 |
| WakixPitolisant Hcl | 11 | $87,411 |
| Breo ElliptaFluticasone/Vilanterol | 117 | $61,947 |
| MounjaroTirzepatide | 31 | $41,376 |
| Arnuity ElliptaFluticasone Furoate | 95 | $36,696 |
| SymbicortBudesonide/Formoterol Fumarate | 79 | $31,489 |
| SunosiSolriamfetol Hcl | 32 | $27,877 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $20,326 |
| NuvigilArmodafinil | 12 | $13,555 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 73 | $13,524 |
| Modafinil | 158 | $10,759 |
| Qvar RedihalerBeclomethasone Dipropionate | 33 | $10,332 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 52 | $10,272 |
| DuleraMometasone/Formoterol | 24 | $9,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $702 | $348,392510 claims |
| Harmony Biosciences LLCWakix | $577 | $87,41111 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $498 | $51,815107 claims |
| Axsome Therapeutics, Inc.Sunosi | $185 | $27,87732 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $146 | $10,33233 claims |
| MerckDulera | $27 | $9,99624 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $17 | $8,59914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Saint Louis
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
- Alexander ChenSaint Louis$951K
- Daniel RosenbluthSaint Louis$903K
- Derek ByersSaint Louis$835K
- Jeffrey AtkinsonSaint Louis$604K
- James KringsSaint Louis$505K
- Colleen McEvoySaint Louis$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.